Rotavirus is a virus that causes gastroenteritis, an inflammation of the stomach and intestines. It is one of the most common causes of diarrhea in infants and young children. Rotavirus infection can be life-threatening to infants and young children, especially those who are malnourished or have other health problems. The virus spreads easily from person to person through contact with contaminated hands, surfaces, or objects.
The global rotavirus infections drug market is expected to grow at a CAGR of 5% during the forecast period (2016-2030). The growth in this market can be attributed to factors such as increasing incidence rates of rotavirus infections among children globally; increasing awareness about prevention methods for rotavirus infections; increase in number of vaccines available for treatment against rotaviruses; and growing demand for antiviral drugs due to their efficacy against viral diseases such as influenza A H1N1 pandemic 2009.
Rotavirus is a virus that causes diarrhea. Rotavirus infections are usually mild and last for about a week. The virus spreads easily from person to person, especially in places where people live in close quarters, such as daycare centers and nursing homes.
Rotavirus Drug is used to treat rotavirus infection (diarrhea) in children who are at least 6 months old.
- The global rotavirus vaccine market is expected to grow at a CAGR of 8.2% from 2017 to 2025, according to a new study by Grand View Research, Inc .
- The global rotavirus vaccine market is expected to reach USD 1,890 million by 2025, according to a new study by Grand View Research, Inc .
- Rotavirus infections are the most common cause of severe diarrhea in children under five years old and account for more than half of all hospitalizations for diarrhea in this age group worldwide.
Industry Growth Insights published a new data on “Rotavirus Infections Drug Market”. The research report is titled “Rotavirus Infections Drug Market research by Types (RV-3BB, RV-625, UMN-2001, Rotavac-5C, Others), By Applications (Clinic, Hospital, Others), By Players/Companies Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, Medicago Inc, Nanotherapeutics Inc, Serum Institute of India Ltd, UMN Pharma Inc, Wuhan Institute of Biological Products Co Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rotavirus Infections Drug Market Research Report
By Type
RV-3BB, RV-625, UMN-2001, Rotavac-5C, Others
By Application
Clinic, Hospital, Others
By Companies
Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, Medicago Inc, Nanotherapeutics Inc, Serum Institute of India Ltd, UMN Pharma Inc, Wuhan Institute of Biological Products Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Rotavirus Infections Drug Market Report Segments:
The global Rotavirus Infections Drug market is segmented on the basis of:
Types
RV-3BB, RV-625, UMN-2001, Rotavac-5C, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Beijing Minhai Biotechnology Co Ltd
- Bharat Biotech International Ltd
- Biological E Ltd
- Curevac AG
- Medicago Inc
- Nanotherapeutics Inc
- Serum Institute of India Ltd
- UMN Pharma Inc
- Wuhan Institute of Biological Products Co Ltd
Highlights of The Rotavirus Infections Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RV-3BB
- RV-625
- UMN-2001
- Rotavac-5C
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rotavirus Infections Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rotavirus infections are a type of virus that can cause diarrhea in children and adults. Rotavirus is spread through contact with fecal matter, such as vomit or diarrhea. It can also be spread through close contact with an infected person, such as when someone is sick or when the person has touched something that has been contaminated with rotavirus. There is no specific treatment for rotavirus infections, but they usually go away on their own after a few days.
Some of the key players operating in the rotavirus infections drug market are Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Curevac AG, Medicago Inc, Nanotherapeutics Inc, Serum Institute of India Ltd, UMN Pharma Inc, Wuhan Institute of Biological Products Co Ltd.
The rotavirus infections drug market is expected to grow at a compound annual growth rate of 5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rotavirus Infections Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rotavirus Infections Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rotavirus Infections Drug Market - Supply Chain
4.5. Global Rotavirus Infections Drug Market Forecast
4.5.1. Rotavirus Infections Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rotavirus Infections Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rotavirus Infections Drug Market Absolute $ Opportunity
5. Global Rotavirus Infections Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rotavirus Infections Drug Market Size and Volume Forecast by Type
5.3.1. RV-3BB
5.3.2. RV-625
5.3.3. UMN-2001
5.3.4. Rotavac-5C
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rotavirus Infections Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rotavirus Infections Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rotavirus Infections Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rotavirus Infections Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rotavirus Infections Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rotavirus Infections Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rotavirus Infections Drug Demand Share Forecast, 2019-2026
9. North America Rotavirus Infections Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rotavirus Infections Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rotavirus Infections Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rotavirus Infections Drug Market Size and Volume Forecast by Type
9.7.1. RV-3BB
9.7.2. RV-625
9.7.3. UMN-2001
9.7.4. Rotavac-5C
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rotavirus Infections Drug Demand Share Forecast, 2019-2026
10. Latin America Rotavirus Infections Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rotavirus Infections Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rotavirus Infections Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rotavirus Infections Drug Market Size and Volume Forecast by Type
10.7.1. RV-3BB
10.7.2. RV-625
10.7.3. UMN-2001
10.7.4. Rotavac-5C
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rotavirus Infections Drug Demand Share Forecast, 2019-2026
11. Europe Rotavirus Infections Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rotavirus Infections Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rotavirus Infections Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rotavirus Infections Drug Market Size and Volume Forecast by Type
11.7.1. RV-3BB
11.7.2. RV-625
11.7.3. UMN-2001
11.7.4. Rotavac-5C
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rotavirus Infections Drug Demand Share, 2019-2026
12. Asia Pacific Rotavirus Infections Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rotavirus Infections Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rotavirus Infections Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rotavirus Infections Drug Market Size and Volume Forecast by Type
12.7.1. RV-3BB
12.7.2. RV-625
12.7.3. UMN-2001
12.7.4. Rotavac-5C
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rotavirus Infections Drug Demand Share, 2019-2026
13. Middle East & Africa Rotavirus Infections Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rotavirus Infections Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rotavirus Infections Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rotavirus Infections Drug Market Size and Volume Forecast by Type
13.7.1. RV-3BB
13.7.2. RV-625
13.7.3. UMN-2001
13.7.4. Rotavac-5C
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rotavirus Infections Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Rotavirus Infections Drug Market: Market Share Analysis
14.2. Rotavirus Infections Drug Distributors and Customers
14.3. Rotavirus Infections Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Beijing Minhai Biotechnology Co Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bharat Biotech International Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biological E Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Curevac AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Medicago Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Nanotherapeutics Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Serum Institute of India Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. UMN Pharma Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Wuhan Institute of Biological Products Co Ltd
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
